Coronavirus vaccine composition, method and use thereof
A recombinant subunit vaccine with trimerized S protein peptides addresses the challenge of neutralizing SARS-CoV-2 variants by inducing broad immune responses, enhancing protection against emerging strains.
JP2026518467APending Publication Date: 2026-06-08SICHUAN CLOVER BIOLOGICAL PHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SICHUAN CLOVER BIOLOGICAL PHARMACEUTICAL CO LTD
- Filing Date
- 2024-05-30
- Publication Date
- 2026-06-08
Smart Images
Figure 2026518467000071 
Figure 2026518467000072 
Figure 2026518467000073
Abstract
The present invention relates to an immunogenic composition comprising a recombinant peptide and a protein, wherein the recombinant peptide and protein comprises a coronavirus antigen and an immunogen, for example, SARS-CoV-2 coronavirus Hu-1, its variant omicron (BA.5 and / or XBB.1.5) mutant, and / or other mutant S protein peptides or fragments thereof, variants, or mutant sequences, and chimeric antigens and immunogens. The immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked by in-frame fusion to the C-terminal portion of self-trimerizable collagen to form a trimerized fusion protein linked by disulfide bonds. The immunogenic composition can be used to induce an immune response and can be used in vaccine compositions. Methods for producing recombinant peptides and proteins, methods for prevention, treatment, and / or diagnosis, and related kits are further provided.
Need to check novelty before this filing date? Find Prior Art